Table 2 Observed adverse events following IGEV-Bv salvage and Bv consolidation

From: Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

Adverse event Entire cohort (n = 28)
Neutropenia grades 3–4, n (%) 27 (96)
Thrombocytopenia grades 3–4, n (%) 25 (89)
Blood transfusion units, median (range) 2 (0–11)
Mucositis, n (%)
  Grades 1–2 5 (18)
  Grade 3 1 (4)
Febrile neutropenia, n (%) 16 (57)
Peripheral neuropathy on salvage, n (%)
  Grades 1–2 2 (7)
  Grade 3 1 (4)
Diarrhea, n (%) 6 (21)
Transaminitis grades 3–4, n (%) 2 (7)
Acute renal injury, n (%) 0
ICU transfer, n (%) 0
Bv consolidation, n (%) 18 (64)
Indication for Bv consolidation, n (%)
  Remission < 12 Months 13 (72)
  B-symptoms at Relapse 3 (17)
  Extranodal Relapse 2 (11)
Total doses of Bv delivered, median (range) 15 (6–16)
Filgrastim given during Bv consolidation, n (%) 7 (39)
Peripheral neuropathy on consolidation, n (%)
  Grades 1–2 4 (22)
  Grade 3 1 (5)
 Bv dose reduced due to AE, n (%) 6 (33)
  1. HCT hematopoietic stem cell transplant, ICU intensive care unit, IGEV-Bv ifosfamide, gemcitabine, and vinorelbine with brentuximab vedotin, AE adverse events